ATNM · Actinium Pharmaceuticals, Inc.
Market Cap
$31.76M
Shares
31.44M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.01
Open$1.00
Day$0.97–1.03
52W close$0.75–1.78
Avg vol 30d154K
Short int769K · 2.4% float · 3.4d
Short vol43%
DataAug 2020–Aug 2026
Filing10-Q · Aug 7
Raw chart and full-history price indicators begin at the captured split on Aug 11, 2020; bars on opposite sides are not compared.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 7, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.4 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−14%
below
Price vs 50-day avg
+7%
above
RSI (14)
54
neutral
MACD trend
Positive
52-week position
25%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+21%
trailing
6-month return
−16%
trailing
YTD return
−26%
this year
Relative strength
−29%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-13% holders QoQ · +6 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.44% of float · ▼ -2.3% MoM · 3.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
48 holders — near 3-yr low, contrarian setup
Squeeze score
58
elevated · 0–100
Fundamentals
Revenue growth
+11%
Y/Y
Gross margin
0%
EPS growth
+14%
Y/Y
Free cash flow
$-24.7M
Valuation
P/E 2.9
below peers
Balance sheet
$13.7M
net cash
Quant / Vol
risk profile
Volatility
66%
annualized · 1-yr
Max drawdown
−58%
past year
ATR
6.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−14%
Bearish
Price vs 50-day avg
+7%
Bullish
RSI (14)
54
Neutral
MACD trend
Positive
Bullish
52-week position
25%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-13% holders QoQ · +6 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.44% of float · ▼ -2.3% MoM · 3.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
48 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $1
Now $1 · 25%
Range high $2
vs 200-day avg -14%
vs 50-day avg +7%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ATNM
this stock
Actinium Pharmaceuticals, Inc.
|
$31.76M | -25.7% | — | 2.9 | 2.4% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$137.30B | +19.5% | +46.2% | 31.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.27B | +2.9% | +20.8% | 19.6 | 2.3% |
|
ARGX
Argenx SE
|
$63.63B | +21.7% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.92B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
Raw-price comparisons begin at the captured split on Aug 11, 2020; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ATNM | -8.2% | +20.7% | -15.8% | +20.7% | -25.7% |
| SPY | +0.5% | +3.0% | +13.4% | +3.0% | +12.8% |
| vs SPY | -8.7% | +17.7% | -29.3% | +17.7% | -38.6% |
Key facts
CIK
1388320
CUSIP
00507W206
13F (30d)
43 filings
43 filers
Visit website
Investor relations